Tome Bioscience

Tome Biosciences is a genome-editing therapeutics company founded in 2021 and based in Watertown, Massachusetts. It develops programmable genomic integration (PGI) technology that pairs the site-specificity of CRISPR/Cas with integrase enzymes to insert genetic sequences of virtually any size into the genome without relying on double-strand DNA breaks. The company was cofounded by Omar Abudayyeh and Jonathan Gootenberg, formerly of MIT's McGovern Institute, and raised roughly $213M across Series A and B financing led in part by a16z. Its stated programs target integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune conditions. Tome is a biopharmaceutical R&D company with no public API, developer portal, SDKs, or machine-readable API surface; its documented website (tome.bio) does not currently resolve. It is tracked in the API Evangelist network as an a16z portfolio company / enrichment lead rather than an API producer.

Tome Bioscience is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Genome Editing, Gene Therapy, and CRISPR.

🌐 Visit website 📡 Source on GitHub
2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyGenome EditingGene TherapyCRISPRLife SciencesTherapeutics

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 2.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 0.0 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/tome-bioscience: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

apis.yml Raw ↑ 
aid: tome-bioscience
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/tome-bioscience.png
name: Tome Bioscience
description: Tome Biosciences is a genome-editing therapeutics company founded in 2021 and based in Watertown, Massachusetts.
  It develops programmable genomic integration (PGI) technology that pairs the site-specificity of CRISPR/Cas with integrase
  enzymes to insert genetic sequences of virtually any size into the genome without relying on double-strand DNA breaks. The
  company was cofounded by Omar Abudayyeh and Jonathan Gootenberg, formerly of MIT's McGovern Institute, and raised roughly
  $213M across Series A and B financing led in part by a16z. Its stated programs target integrative gene therapies for monogenic
  liver diseases and cell therapies for autoimmune conditions. Tome is a biopharmaceutical R&D company with no public API,
  developer portal, SDKs, or machine-readable API surface; its documented website (tome.bio) does not currently resolve. It
  is tracked in the API Evangelist network as an a16z portfolio company / enrichment lead rather than an API producer.
url: https://raw.githubusercontent.com/api-evangelist/tome-bioscience/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
x-tier: stub
x-tier-reason: portfolio-lead
x-industry: Biotechnology
x-headquarters: Watertown, Massachusetts, USA
x-founded: '2021'
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Genome Editing
- Gene Therapy
- CRISPR
- Life Sciences
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: nochange
  artifacts_added: 0
  pass: local-v1